Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002504398 | SCV002814892 | uncertain significance | Diabetes mellitus, transient neonatal, 2; Hyperinsulinemic hypoglycemia, familial, 1; Leucine-induced hypoglycemia; Type 2 diabetes mellitus; Diabetes mellitus, permanent neonatal 3 | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001278393 | SCV001465406 | uncertain significance | Hereditary hyperinsulinism | 2020-04-10 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004734086 | SCV005353454 | uncertain significance | ABCC8-related disorder | 2024-04-26 | no assertion criteria provided | clinical testing | The ABCC8 c.3493G>A variant is predicted to result in the amino acid substitution p.Val1165Met. This variant has been reported in individuals with congenital hyperinsulinism and diabetes (Table S4, De Franco et al 2020. PubMed ID: 32027066; Table 4, Elashi et al. 2022. PubMed ID: 36613572). This variant is reported in 0.059% of alleles in individuals of South Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |